In a report published Monday, Canaccord Genuity reiterated its Buy rating on Hologic HOLX, and raised its price target from $23.00 to $27.00.
Canaccord Genuity noted, “We reiterate our BUY rating and increase our price target to $27 from $23 as we see a favorable risk/reward profile in HOLX shares. As a result of further analysis of the Gen-Probe acquisition – including a detailed scenario analysis for the combined company presented in this report – we think both our new EPS estimates and valuation assumptions could prove conservative, and thus would accumulate shares at current levels.”
Hologic closed on Friday at $20.74.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in